Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00219011 |
This study was designed to determine if patients, who have both high blood pressure and heart failure and are currently receiving drug treatment for heart failure, have an improvement in their heart failure signs and symptoms and other indicators of heart failure after being treated with aliskiren on top of their current heart failure treatment. Aliskiren is an investigational drug; its safety will also be evaluated in this trial.
Condition | Intervention | Phase |
---|---|---|
Heart Failure |
Drug: aliskiren |
Phase III |
Study Type: | Interventional |
Study Design: | Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Twelve-Week, Randomized, Double-Blind, Multi-Center, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Aliskiren 150 mg When Added to Standard Therapy in Hypertensive Patients With Stable Heart Failure |
Estimated Enrollment: | 280 |
Study Start Date: | May 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined exclusion criteria may apply.
United States, New Jersey | |
Novartis Pharmaceuticals | |
East Hanover, New Jersey, United States | |
Germany | |
Investigative Centers, Germany |
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Study ID Numbers: | CSPP100A2313 |
Study First Received: | September 12, 2005 |
Last Updated: | April 26, 2007 |
ClinicalTrials.gov Identifier: | NCT00219011 |
Health Authority: | United States: Food and Drug Administration |
Aliskiren, heart failure,hypertension |
Heart Failure Heart Diseases Hypertension |
Cardiovascular Diseases |